Skip to content
DataLookout
Menu

NCT05574101

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 24 versions: 14 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Oct 6, 2026 to Oct 6, 2027
    • Eligibility criteria expanded, about 40 words
  2. Notable Primary endpoint revisedv23
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 13 of 13 sites
    v15
  4. Minor Site details revised at 1 of 13 sitesv13
  5. Minor Study sites: 14 to 13v12
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Site details revised at 1 of 14 sitesv10
  2. Minor Site details revised at 1 of 14 sitesv9
  3. Notable Eligibility criteria expanded, about 17 wordsv7
  4. Notable Primary and study completion dates: Oct 6, 2024 to Oct 6, 2026
    • Site details revised at 1 of 14 sites
    v6
  5. Minor Site details revised at 1 of 14 sitesv5
  6. Minor Study sites: 12 to 14v4
  7. Minor Site details revised at 1 of 12 sitesv3
  8. Minor Study sites: 13 to 12v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Event Free Survival
Timeframe: 18 months

Arms and interventions

Participants with locally advanced, unresectable cutaneous squamous cell carcinoma/CSCCExperimental

Participants have locally advanced, unresectable cutaneous squamous cell carcinoma/CSCC

Drugs: Cemiplimab

Radiation: Radiotherapy

Sites

13 sites in 1 country